- Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.
Kesselheim Aaron S et al. JAMA 2016 Oct
- Ethical and Policy Issues in Newborn Screening of Children for Neurologic and Developmental Disorders.
Ross Lainie Friedman et al. Pediatr. Clin. North Am. 2015 Jun 62(3) 787-798
lunes, 26 de febrero de 2018
Muscular dystrophy [NEW TOPIC PAGE]
From Genomics & Health Impact Scan Database
This database includes published scientific literature on evidence-based translation of genomic discoveries into improved health care and disease prevention that have a potential impact on population health.